XBiotech Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report; selected unaudited Q4 results are included. XBiotech is a pre-commercial biopharmaceutical company developing naturally derived “True Human” monoclonal antibodies. It has no approved products and has not generated product-sales revenue.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $44.0 million | None |
| Gross profit / margin | $9.4 million / approximately 21.5% | Not applicable |
| Operating expenses | $27.7 million | $31.2 million |
| Operating loss | $18.3 million | $31.2 million |
| Net income (loss) | $(11.2) million | $668.6 million |
| Net loss per share, basic and diluted | $(0.36) | Basic $17.17; diluted $14.44 |
| Cash and cash equivalents at year-end | $237.4 million | $714.6 million |
| Net cash used in operating activities | $65.1 million | $18.3 million |
FY2020 revenue comprised $18.0 million of Janssen clinical manufacturing revenue, $26.0 million of clinical-trial services revenue (including $20.0 million of pass-through costs and $6.0 million markup), and $22,000 of other revenue. Reported cost of goods sold was $34.5 million. Research and development expense fell 60% to $9.5 million, partly because certain Janssen-related costs were classified as cost of goods sold. General and administrative expense rose 155% to $18.2 million, reflecting higher stock-based compensation, executive compensation, and tender-offer-related fees.
The 2019 profit was exceptional: it included a $750.0 million gain from the Janssen transaction. In February 2020, the company repurchased 14.0 million shares for approximately $420 million, about 32.7% of shares then outstanding. The 2020 cash decline also included $54.1 million of income taxes paid related to 2019 earnings. Cash flow from operations was negative despite management’s statement that Janssen service revenue offset a significant portion of operating expenses.
At December 31, 2020, current assets were $325.9 million and current liabilities were $4.0 million; total liabilities were $5.1 million, including income-tax payables. The filing reports no debt. Assets included a $75.1 million current escrow receivable and a $6.6 million income-tax receivable. The company expected to receive $75 million from the Janssen transaction in 2021. Its 48-acre Austin campus and facilities are owned debt-free.
Business developments and outlook
- XBiotech reported filing an IND for a new anti-IL-1α candidate and planned to bring more than one candidate into clinical studies beginning in 2021, with cancer, stroke, and arthritis among potential indications. These were plans, not completed clinical milestones.
- The company continued infectious-disease research, including candidates for RSV, varicella, influenza, and S. aureus. It reported developing an influenza antibody cocktail and cited prior Phase I/II S. aureus study results, but these programs remain subject to further development and regulatory risk.
- Janssen agreements supported 2020 manufacturing and clinical-trial services. The manufacturing agreement provides quarterly payments of $4.5 million for up to two years and is scheduled to expire December 31, 2021; Janssen may terminate on 60 days’ notice. The clinical-trial services agreement is also terminable by Janssen on 30 days’ notice. The company expected sufficient cash for research and development over the following year, while also warning that it expects significant operating losses and may need additional capital.
- The 2019 asset sale provided $675 million upfront, with a further $75 million expected in 2021 and up to $600 million in contingent milestones. Milestones depend on Janssen’s decisions, regulatory approvals, and other conditions; none is assured. XBiotech retained rights to develop anti-IL-1α antibodies outside dermatology, subject to the transaction agreements.
- COVID-19 disrupted syringe supplies and delayed Janssen manufacturing orders during 2020; the orders were fulfilled by year-end. The filing warns of possible further supply-chain, clinical-trial, and regulatory delays.
Key risks, contingencies, and other disclosures
- No product is approved, and the company has no product-sales revenue. Clinical, regulatory, reimbursement, manufacturing, commercialization, and financing outcomes remain uncertain; sustained profitability is not assured.
- Janssen service revenue is time-limited and may end or be reduced earlier under contractual termination provisions. Failure to meet manufacturing obligations could also affect payments and business relationships.
- Other principal risks include trial enrollment and safety outcomes, competition, intellectual-property protection and infringement claims, reliance on key personnel, and potential dilution or unfavorable financing terms.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end. The auditor issued an unqualified opinion on the financial statements and identified accrued clinical-trial costs as a critical audit matter; the company was not required to obtain an auditor attestation on internal-control effectiveness.
- No cash dividends have been paid or declared, and none is expected in the foreseeable future. The filing says the company was not exposed to material market risk from financial instruments, interest rates, commodities, or foreign currency, and did not hedge those risks.
Most important facts for investors to verify
- Whether the expected $75 million Janssen payment was received in 2021, and the status, remaining duration, and termination terms of the manufacturing and clinical-services agreements.
- Cash burn and runway after the $420 million repurchase, including the distinction between $237.4 million of year-end cash and other current assets such as escrow and tax receivables.
- Progress and regulatory status of the anti-IL-1α IND and planned clinical programs, and whether any pipeline claims are supported by subsequent trial data.
- The company’s ability to replace Janssen-related revenue after the manufacturing agreement ends, and whether additional financing will be needed.
- Potential receipt of contingent Janssen milestones, which are not guaranteed, and the implications of the dermatology restriction and retained intellectual-property rights.